FDA Defends Its Turf, Argues Preemption In Tenn. Pacesetter Case
This article was originally published in The Gray Sheet
Executive Summary
A state court jury should not be allowed to determine whether a device is fully PMA-approved and thus preempted from tort litigation, according to FDA